

# AUTHOR INDEX FOR VOLUME 16

- Abuchaibe, O. See Calvo, F. A.; Hidalgo, O. F.
- Adelson, M. D. See Broun, G. O.
- Aisner, S. See Bonomi, P. D.
- Amato, D. See Marcial, V. A.
- Amey, F. See Petrovich, Z.
- Amoroso, D. See Pronzato, P.
- Andreoli, C. See Tomio, L.
- Ang, P.-T.
- Soh, L.-T.; Sng, I.; Chua, E.-J.; Ong, Y.-W.: MACOP-B in advanced non-Hodgkin's lymphoma, 315
- Anhalt, D. P. See Croghan, M. K.
- Ansari, R. See Mandanas, R.
- Aozasa, K. See Ikeda, H.
- Aristu, J. J. See Calvo, F. A.
- Armand, J. P. See Roché, H.
- Aron, B. S. See Montebello, J. F.
- Artal, A. See Barón, M. G.
- Arthur, K. A. See Stone, R. M.
- Asbell, S. O. See Perez, C. A.
- Asbury, R. F.
- Blessing, J. A.; Look, K. Y.; Clarke-Pearson, D.; Homesley, H. D.: A gynecologic oncology group phase II study of amonafide (NSC 308847) in epithelial ovarian cancer, 529
- Atlan, D. See Azagury, M.
- Austin, J.
- Convery, K.: Age-race interaction in prostatic adenocarcinoma treated with external beam irradiation, 140
- Azagury, M.
- Chevallier, B.; Atlan, D.; Graic, Y.; Dayot, J. P.; Thomine, E.: VP-16, cisplatin, doxorubicin, and bleomycin in metastatic merkel cell carcinoma: Report of a case with long-term remission, 102
- Azarnia, N. See Cody, R.
- Azinovic, I. See Calvo, F. A.
- Baert, L. See Petrovich, Z.
- Baethge, B. A. See Mills, G. M.
- Baker, L. H. See Kraut, E. H.
- Balaban, E. P. See Sheehan, R. G.
- Barletta, A. See Lena, M. D.
- Barón, J. M. See Barón, M. G.
- Barón, M. G.
- Artal, A.; Garrido, P.; Girón, C. G.; Ordóñez, A.; Feliu, J.; Berrocal, A.; Barón, J. M.: Randomized phase II trial comparing two chemotherapy combinations for non-small cell lung cancer: Mitomycin, ifosfamide, and cisplatin versus vindesine, ifosfamide, and cisplatin, 310
- Zamora, P.; Ordóñez, A.; Espinosa, E.: (Letter), 183
- Barrett, R. J. See Feun, L. G.; Homesley, H. D.
- Blessing, J. A.; Homesley, H. D.; Twigg, L.; Webster, K. D.: Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma: A phase II study of the gynecologic oncology group, 494
- Barry, A. See Fontanesi, J.
- Bastin, K.
- Buchler, D.; Stitt, J.; Shanahan, T.; Pola, Y.; Paliwal, B.; Kinsella, T.: Resource utilization: High dose rate versus low dose rate brachytherapy for gynecologic cancer, 256
- Beecham, J. B. See Malfetano, J.
- Benasso, M.
- Merlano, M.; Blengio, F.; Cavallari, M.; Rosso, R.; Toma, S.: Concomitant alpha-interferon and chemotherapy in advanced squamous cell carcinoma of the head and neck, 465
- Berian, J. M. See Calvo, F. A.
- Bernal, E. T. See Gerson, R.
- Berrocal, A. See Barón, M. G.
- Bertelli, G. See Pronzato, P.
- Bichler, K. H. See Petrovich, Z.
- Bilbao, I. See Hidalgo, O. F.
- Biscotti, C. V. See Dass, K. K.
- Blengio, F. See Benasso, M.
- Blessing, J. A. See Asbury, R. F.; Barrett, R. J.; Broun, G. O.; Feun, L. G.; Malfetano, J. H.; Muss, H. B.
- Block, C. See Kantoff, P. W.
- Blumenreich, M. See Joseph, G.
- Bonomi, P. D.
- Finkelstein, D.; Aisner, S.; Ettinger, D.: EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma, 342
- Boyd, S. D. See Petrovich, Z.
- Bradof, J. E. See Kraut, E. H.
- Brady, L. W. See Calvo, F. A.; Hernandez, J. C.; Marcial, V. A.; Petrovich, Z.; Seegenschmiedt, M. H.
- Memorial: Clarence E. Ehrlich, M.D., 185
- Breslow, N. See Finkelstein, J. Z.
- Brodsky, I.
- Review of *Current therapy in hematology-oncology*, 4th ed., 180
- Bronn, D. See Konski, A.
- Broun, G. O.
- Sledge, G. W.; Einhorn, L. H.; Tricot, G. J. K.: High-dose carboplatin and mitoxantrone with autologous bone marrow support in the treatment of advanced breast cancer, 9
- Broun, G. O.
- Blessing, J. A.; Eddy, G. L.; Adelson, M. D.: A phase II trial of vincristine in advanced or recurrent endometrial carcinoma: A gynecologic oncology group study, 18
- Bruner, J. M. See Seong, D. C.
- Bruskewitz, R. C. See Petrovich, Z.
- Buchler, D. See Bastin, K.
- Buchler, D. A. See Petereit, D. G.
- Bump, R. C. See Homesley, H. D.
- Bundy, B. N. See Malfetano, J.
- Buzdar, A. U. See Cohen, P. R.
- Calcaterra, T. C. See Mark, R. J.
- Calvo, F. A.
- Aristu, J. J.; Abuchaibe, O.; Rebollo, J.; Hidalgo, O. F.; Zudaire, J.; Berian, J. M.; Azinovic, I.: Intraoperative and external preoperative radiotherapy in invasive bladder cancer: Effect of neoadjuvant chemotherapy in tumor downstaging, 61
- Micaily, B.; Brady, L. W.: Intraoperative radiotherapy: A positive view, 418
- Calzavara, F. See Tomio, L.
- Cattan, A. See Roché, H.
- Cavallari, M. See Benasso, M.
- Cetas, T. C. See Croghan, M. K.
- Chahbazian, C.
- Radiation therapy for the palliation of pain in advanced cancer, 444

- Chalal, J. A. See Seegenschmiedt, M. H.  
 Champlin, R. E. See Seong, D. C.  
 Chan, S. L.  
 —Kagan, A. R.; Streeter, O. E., Jr.; Ryoo, M. C.: Outcome of care: Complications from radiation therapy treatment, 81  
 Chang, A.  
 —Hunt, M.; Parkinson, D. R.; Hochster, H.; Smith, T. J.: Phase II trial of carboplatin in patients with metastatic malignant melanoma: A report from the eastern cooperative oncology group, 152  
 Chevallier, B. See Azagury, M.  
 —Roche, H.; Olivier, J. P.; Chollet, P.; Hurteloup, P.: Inflammatory breast cancer: Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate, 223  
 Chiarion-Sileni, V. See Tomio, L.  
 Chlebowski, R. T.  
 Breast cancer adjuvant therapy after two decades (clinical progress but a "partial circle" in investigation), 532  
 Chollet, P. See Chevallier, B.  
 Chua, E.-J. See Ang, P.-T.  
 Clark, R. A. See Kris, M. G.  
 Clark, W. C. See Fontanesi, J.  
 Clarke-Pearson, D. See Asbury, R. F.  
 Clover, L. L.  
 —Hazuka, M. B.; Kinzie, J. J.: Spinal cord ependymomas treated with surgery and radiation therapy: A review of 11 cases, 350  
 Cody, R.  
 —Stewart, D.; DeForni, M.; Moore, M.; Dallaire, B.; Azarnia, N.; Gyves, J.: Multicenter phase II study of brequinar sodium in patients with advanced breast cancer, 526  
 Cohen, P. R.  
 —Buzdar, A. U.: Metastatic breast carcinoma mimicking an acute paronychia of the great toe: Case report and review of subungual metastases: A case report, 86  
 —Hypertrophic pulmonary osteoarthropathy and tripe palms in a man with squamous cell carcinoma of the larynx and lung: Report of a case and review of cutaneous paraneoplastic syndromes associated with laryngeal and lung malignancies: A case report, 268  
 Convery, K. See Austin, J.  
 Corringham, R. See Goss, G. D.  
 Corringham, S. See Goss, G. D.  
 Cowan, K. H. See Johnston, P. G.  
 Creagan, E. T.  
 —Schaid, D. J.; Hartmann, L. C.; Loprinzi, C. L.: A phase II study of 5,6-dihydro-5-azacytidine hydrochloride in disseminated malignant melanoma, 243  
 —Schutt, A. J.; Richardson, R. L.; Schaid, D. J.: Phase II trial of VP-16, bleomycin, and cisplatin in patients with advanced nonsquamous cell head and neck neoplasms, 291  
 Crino, L. See Davis, S.  
 Cripps, M. C. See Stewart, D. J.  
 Croghan, M. K.  
 —Shimm, D. S.; Hynynen, K. H.; Anhalt, D. P.; Valencic, S. L.; Fletcher, A. M.; Kittelson, J. M.; Cetas, T. C.: A phase I study of the toxicity of regional hyperthermia with systemic warming, 354  
 Cuevas, M. See Lena, M. D.  
 Dallaire, B. See Cody, R.  
 Dana, B. See Fletcher, W. S.  
 D'Angio, G. J. See Finklestein, J. Z.  
 Daniels, D. S. See Fletcher, W. S.  
 Darwish, S. See Davis, S.  
 Dass, K. K.  
 —Biscotti, C. V.; Webster, K.; Saxton, J. P.: Malignant mixed müllerian tumors of the ovary: An analysis of two long-term survivors, 346  
 Davidson, B. S.  
 —Lee, J. E.; Dodd, L. G.; Dimopoulos, M. A.; Evans, D. B.: Extramedullary plasmacytoma of the pancreas: Clinical case reports, 363  
 Davis, L. W. See Laramore, G. E.  
 Davis, S.  
 —Crino, L.; Tonato, M.; Darwish, S.; Pelicci, P. G.; Grignani, F.: A prospective analysis of chemotherapy following surgical resection of clinical stage I-II small-cell lung cancer, 93  
 Dayot, J. P. See Azagury, M.  
 de Alava, E. F. See González-Manzano, R.  
 de Wit, R.  
 —Verweij, J.; Slingerland, R.; Stoter, G.: Piritrexim-induced pulmonary toxicity, 146  
 DeForni, M. See Cody, R.  
 del Regato, J. A.  
 Introduction, 369  
 DePotter, P. See Hernandez, J. C.  
 DePriest, P. See Maruyama, Y.  
 Dhaliwal, H. See Goss, G. D.  
 Difino, S. See Luikart, S. D.  
 Dimopoulos, M. A. See Davidson, B. S.  
 Dixon, C. See Petrovich, Z.  
 Djulbegovic, B. See Joseph, G.  
 Dobelbower, R. R., Jr. See Konski, A.  
 Dodd, L. G. See Davidson, B. S.  
 Dowling, S. See Halperin, E. C.  
 DuBeshter, B. See Muss, H. B.  
 Echo, D. A. V. See Luikart, S. D.  
 Eddy, G. L. See Broun, G. O.  
 Eddy, T. See Fontanesi, J.  
 Einhorn, L. H. See Broun, E. R.; Mandanas, R.  
 Emami, B. See Perez, C. A.  
 Erickson, B. A.  
 —Wilson, J. F.: Nasopharyngeal brachytherapy, 424  
 Erwin, T. J. See Tannock, I. F.  
 Espinosa, E. See Barón, M. G.  
 Ettinger, D. See Bonomi, P. D.  
 Evans, D. B. See Davidson, B. S.  
 Falkson, C. B. See Falkson, C. I.  
 Falkson, C. I.  
 —Galkson, G.; Falkson, C. B.; Falkson, H. C.: A randomized trial of mitomycin-C (M) versus mitomycin-C plus high-dose medroxyprogesterone acetate (MMPA) in the treatment of patients with advanced breast cancer, 14  
 Falkson, G. See Falkson, C. I.  
 Falkson, H. C. See Falkson, C. I.  
 Fargeot, P. See Roché, H.  
 Favaretto, A. See Tomio, L.  
 Fede, A. See Tomio, L.  
 Feliu, J. See Barón, M. G.  
 Fenig, E.  
 —Lurie, H.; Sulkes, A.: The use of cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of merkel cell carcinoma, 54  
 Feola, J. M. See Maruyama, Y.  
 Feun, L. G.  
 —Blessing, J. A.; Barrett, R. J.; Hanjani, P.: A phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix, 506  
 Fingert, H. See Stewart, D. J.  
 Finkelstein, D. See Bonomi, P. D.

- Finklestein, J. Z.**  
—Norkool, P.; Green, D. M.; Breslow, N.; D'Angio, G. J.: Diastolic hypertension in Wilms' tumor survivors: A late effect of treatment?: A report from the national Wilms' tumor study group, 201
- Fiorentino, M.** See Tomio, L.
- Fleming, T.** See Kraut, E. H.
- Fletcher, A. M.** See Croghan, M. K.
- Fletcher, W. S.**  
—Daniels, D. S.; Sondak, V. K.; Dana, B.; Townsend, R.; Hynes, H. E.; Hutchins, L. F.; Pancoast, J. R.: Evaluation of cisplatin and DTIC in inoperable stage III and IV melanoma: A southwest oncology group study, 359
- Fontaine, B.** See Tannock, I. F.
- Fontanesi, J.**  
—Clark, W. C.; Weir, A.; Barry, A.; Kumar, P.; Miller, A.; Eddy, T.; Tai, D.; Kun, L. E.: Interstitial iodine 125 and concomitant cisplatin followed by hyperfractionated external beam irradiation for malignant supratentorial glioma: Preliminary experience at the University of Tennessee, Memphis, 412
- Forgach, E. S.** See Gerson, R.
- Forness, T. J.** See Ganz, W. I.
- Foxlee, R. H.**  
Computer-aided documentation: Quality, productivity, coding, and enhanced reimbursement, 455
- Francini, F.** See Tomio, L.
- Fraschini, G.** See Theriault, R. L.
- Frenkel, E. P.** See Sheehan, R. G.
- Friso, M. L.** See Tomio, L.
- Frye, D.** See Theriault, R. L.
- Fu, Y. S.** See Mark, R. J.
- Fukumoto, M.** See Nio, Y.
- Fumoleau, P.** See Roché, H.
- Gallion, H. H.** See Maruyama, Y.
- Gallotti, P.** See Pronzato, P.
- Gams, R. A.** See Homesley, H. D.
- Ganz, W. I.**  
—Sridhar, K. S.; Forness, T. J.: Detection of early anthracycline cardiotoxicity by monitoring the peak filling rate, 109
- García-Foncillas, J.** See González-Manzano, R.
- Garrido, P.** See Barón, M. G.
- Gaspar, L.** See Halperin, E. C.
- George, M.** See Kantoff, P. W.
- Gerin-Lajoie, J.** See Stewart, D. J.
- Germond, C.** See Goss, G. D.
- Gerson, R.**  
—Bernal, E. T.; Leon, M. L.; Forgach, E. S.; Irigoyen, C. G.; Godínez, F. G.; González, H. G.: Low toxicity with continuous infusion of high-dose bleomycin in poor prognostic testicular cancer, 323
- Girón, C. G.** See Barón, M. G.
- Glabecke, M. V.** See Roché, H.
- Godínez, F. G.** See Gerson, R.
- Goldberg, J.** See Gryn, J.
- Gondo, H.** See Uchino, J.
- González, H. G.** See Gerson, R.
- González-Manzano, R.**  
—Vieitez, J. M.; Tangco, E.; de Alava, E. F.; Herranz, P.; García-Foncillas, J.: Phase II evaluation of doxorubicin, ifosfamide, and dacarbazine plus amphotericin B in the treatment of metastatic soft tissue sarcomas: A pilot study, 332
- Goss, G. D.**  
—Vincent, M.; Germond, C.; Corringham, S.; Rowen, J.; Dhaliwal, H.; Corringham, R.: Combination chemotherapy with teniposide (VM26) and carboplatin in small cell lung cancer, 295
- Goutsou, M.** See Luikart, S. D.
- Graham, P.**  
—(Letter), 181
- Graic, Y.** See Azagury, M.
- Gralla, R. J.** See Kris, M. G.
- Green, D. M.** See Finklestein, J. Z.
- Green, M. R.** See Luikart, S. D.
- Griffin, J.** See Stone, R. M.
- Griffin, T. W.** See Laramore, G. E.
- Grignani, F.** See Davis, S.
- Gryn, J.**  
—Goldberg, J.; Johnson, E.; Siegel, J.; Inzerillo, J.: The toxicity of daily inhaled amphotericin B, 43
- Guenzi, M.** See Pronzato, P.
- Guiochet, N.** See Roché, H.
- Gupta, S.** See Tannock, I. F.
- Gutterman, J. U.** See Theriault, R. L.
- Gyves, J.** See Cody, R.
- Hadley, T.** See Joseph, G.
- Hahne, W. F.** See Homesley, H. D.; Kris, M. G.
- Halperin, E. C.**  
—Gaspar, L.; Imperato, J.; Salter, M.; Herndon, J., II; Dowling, S.: An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors, 277
- Hamm, J.** See Joseph, G.
- Hanjani, P.** See Feun, L. G.
- Harry, D. S.** See Homesley, H. D.
- Hartmann, L. C.** See Creagan, E. T.
- Hatch, K. D.** See Malfetano, J.
- Hayashi, H.** See Nio, Y.
- Haynes, G.** See Meurk, M. L.
- Hazuka, M. B.** See Clover, L. L.
- Heck, K.** See Homesley, H. D.
- Hempling, R. E.** See Hicks, M. L.
- Hendrickson, F. R.** See Laramore, G. E.
- Heraït, P.** See Roché, H.
- Hernandez, J. C.**  
—Brady, L. W.; Shields, C. L.; Shields, J. A.; DePoter, P.: Conservative treatment of retinoblastoma: The use of plaque brachytherapy, 397
- Herndon, J., II** See Halperin, E. C.
- Herranz, P.** See González-Manzano, R.
- Hickox, P. G.** See Homesley, H. D.
- Hicks, M. L.**  
—Piver, S.; Mas, E.; Hempling, R. E.; Mcauley, M.; Walsh, D. L.: Intraoperative orthovoltage radiation therapy in the treatment of recurrent gynecologic malignancies, 497
- Hidalgo, O. F.** See Calvo, F. A.
- Rebollo, J.; Vieitez, J. M.; Bilbao, I.; Tangco, E.; Abuchaibe, O.; Pardo, F.: Intra-arterial hepatic treatment with carboplatin (CBDCA) and 5-fluorouracil (5-FU) in metastases from colorectal carcinoma, 30**
- Hilsenbeck, S. G.**  
—Raub, W. A., Jr.; Sridhar, K. S.: Prognostic factors in lung cancer based on multivariate analysis, 301
- Hochster, H.** See Chang, A.
- Holmes, F. A.** See Theriault, R. L.
- Homesley, H. D.** See Asbury, R. F.; Barrett, R. J.
- Hahne, W. F.; McLees, B.; Neck, K.; Barrett, R. J.; Lentz, S. S.; Woodlief, L.; Lovelace, J. V.: Randomized comparison of the antiemetic efficacy of a serotonin type 3 receptor antagonist (MDL 72,222) with a high-dose metoclopramide regimen, 175**
- Shemano, I.; Gams, R. A.; Harry, D. S.; Hickox, P. G.; Rebar, R. W.; Bump, R. C.; Mullin, T. J.; Wentz, A. C.; O'Toole,**

- R. V.; Lovelance, J. V.; Lyden, C.: Antiestrogenic potency of toremifene and tamoxifen in postmenopausal women, 117
- Hordijk, G. J.** See Levendag, P. C.
- Hornback, N. B.** See Perez, C. A.
- Hortobagyi, G. N.** See Theriault, R. L.
- Horvath, J. L.** See Montebello, J. F.
- Horwich, A.**
- Memorial: Professor Timothy McElwain, 1
- Hunt, M.** See Chang, A.
- Hurteloup, P.** See Chevallier, B.
- Hutchins, L. F.** See Fletcher, W. S.
- Hynes, H. E.** See Fletcher, W. S.
- Hynynen, K. H.** See Croghan, M. K.
- Ikeda, H.**
- Inoue, T.; Teshima, T.; Murayama, S.; Kozuka, T.; Aozasa, K.: Treatment of indolent non-Hodgkin's lymphoma localized in the head and neck, 72
- Imperato, J.** See Halperin, E. C.
- Inoue, T.** See Ikeda, H.
- Inzerillo, J.** See Gryn, J.
- Irigoyen, C. G.** See Gerson, R.
- Jacobs, A. J.** See Malfetano, J. H.
- Jaiyesimi, I. A.**
- Pazdur, R.: Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal: A clinical case report, 536
- Janjan, N. A.** See Perez, C. A.
- Johnson, E.** See Gryn, J.
- Johnston, P. G.**
- Kleiner, D.; Cowan, K. H.: Fazarabine: A report of response in a patient with multiply relapsed embryonal cell carcinoma, 34
- Joseph, G.**
- Hadley, T.; Djulbegovic, B.; Hamm, J.; Seeger, J.; Blumenreich, M.; Woodcock, T.: High-dose chlorambucil and dexamethasone for relapsed non-Hodgkin's lymphomas, 319
- Kagan, A. R.** See Chan, S. L.; Miller, M. J.
- Preface, 371
- Kantoff, P. W.**
- Block, C.; Letvak, L.; George, M.: 14-day continuous infusion of mitoxantrone in hormone-refractory metastatic adenocarcinoma of the prostate, 489
- Kawabata, K.** See Nio, Y.
- Keiling, R.** See Roché, H.
- Kerbrat, P.** See Roché, H.
- Kinsella, T.** See Bastin, K.
- Kinsella, T. J.** See Petereit, D. G.
- Kinzle, J. J.** See Clover, L. L.
- Kirchmann, E.** See Perez, C. A.
- Kittelson, J. M.** See Croghan, M. K.
- Kleiner, D.** See Johnston, P. G.
- Konski, A.**
- Neisler, J.; Phibbs, G.; Bronn, D.; Dobelbower, R. R., Jr.: The use of intraoperative electron beam radiation therapy in the treatment of para-aortic metastases from gynecologic tumors: A pilot study, 67
- Kontkanen, T.** See Maiche, A. G.
- Kozuka, T.** See Ikeda, H.
- Krall, J. M.** See Laramore, G. E.
- Kraut, E. H.**
- Fleming, T.; Macdonald, J. S.; Spiridonidis, C. H.; Bradof, J. E.; Baker, L. H.: Phase II trial of merbarone in pancreatic carcinoma: A southwest oncology group study, 327
- Kris, M. G.**
- Clark, R. A.; Tyson, L. B.; Hahne, W. F.; Pisters, K. M. W.; Gralla, R. J.: Phase II trial of a single intravenous dose of ondansetron in patients receiving cisplatin > 100 mg/m<sup>2</sup>, 77
- Kufe, D. W.** See Stone, R. M.
- Kumar, P.** See Fontanesi, J.
- Kun, L. E.** See Fontanesi, J.
- Lacava, J.** See Lena, M. D.
- Laframboise, G.** See Stewart, D. J.
- Lamothe, A.** See Stewart, D. J.
- Laucker, M. V.** See Roelstraete, A.
- Laramore, G. E.**
- Krall, J. M.; Thomas, F. J.; Russell, K. J.; Maor, M. H.; Hendrickson, F. R.; Martz, K. L.; Griffin, T. W.; Davis, L. W.: Fast neutron radiotherapy for locally advanced prostate cancer: Final report of a radiation therapy oncology group randomized clinical trial, 164
- Lee, J. E.** See Davidson, B. S.
- Lena, M. D.**
- Romero, A.; Rabinovich, M.; Leone, B.; Vallejo, C.; Machiavelli, M.; Cuevas, M.; Rodriguez, R.; Lacava, J.; Perez, J.; Barletta, A.; Paradiso, A.: Metastatic pattern and DNA ploidy in stage IV breast cancer at initial diagnosis: Relation to response and survival, 245
- Lentz, M. A.** See Roché, H.
- Lentz, S. S.** See Homesley, H. D.
- Leon, M. L.** See Gerson, R.
- Leone, B.** See Lena, M. D.
- Letvak, L.** See Kantoff, P. W.
- Levendag, P. C.**
- Ravasz, L. A.; Terhaard, C. H. J.; Hordijk, G. J.: T3 squamous cell carcinoma of the larynx treated by a split-course radiation protocol, 509
- Levitt, S. H.** See Sperduto, P. W.
- Lo, W. K.** See Seong, D. C.
- Lockett, M. A.** See Perez, C. A.
- Look, K. Y.** See Asbury, R. F.
- Loprinzi, C. L.** See Creagan, E. T.
- Lora, O.** See Tomio, L.
- Loreggian, L.** See Tomio, L.
- Lovelace, J. V.** See Homesley, H. D.
- Luikart, S. D.**
- Goutsou, M.; Mitchell, E. D.; Echo, D. A. V.; Modeas, C. R.; Probert, K. J.; O'Donnell, J.; Difino, S.; Perry, M. C.; Green, M. R.: Phase I/II trial of etoposide and carboplatin in extensive small-cell lung cancer: A report from the cancer and leukemia group B, 127
- Lurie, H.** See Fenig, E.
- Lutz, T.** See Mandanas, R.
- Lyden, C.** See Homesley, H. D.
- Macchiarini, P.**
- (Letter), 181
- Macdonald, J. S.** See Kraut, E. H.
- Machiavelli, M.** See Lena, M. D.
- Maiche, A. G.**
- Cancer of unknown primary: A retrospective study based on 109 patients, 26
- Virkkunen, P.; Kontkanen, T.; Möykkynen, K.; Porkka, K.: Bleomycin and mitoxantrone in the treatment of malignant pleural effusions: A comparative study, 50
- Malfetano, J.**
- Beecham, J. B.; Bundy, B. N.; Hatch, K. D.: A phase II trial of medroxyprogesterone acetate in epithelial ovarian cancers: A gynecologic oncology group study, 149
- Malfetano, J. H.**
- Blessing, J. A.; Jacobs, A. J.: A phase II trial of didemnin B



- (NSC #335319) in patients with previously treated epithelial ovarian cancer: A gynecologic oncology group study, 47
- Manatunga, A. K.** See Montebello, J. F.
- Mandanas, R.**
- Einhorn, L. H.; Wheeler, B.; Ansari, R.; Lutz, T.; Miller, M. E.: Carboplatin (CBDCA) plus alpha interferon in metastatic non-small cell lung cancer, 519
- Maor, M. H.** See Laramore, G. E.
- Marcial, V. A.**
- Pajak, T. F.; Rotman, M.; Brady, L. W.; Amato, D.: "Compensated" split-course versus continuous radiation therapy of carcinoma of the tonsillar fossa: Final results of a prospective randomized clinical trial of the radiation therapy oncology group, 389
- Mark, R.** See Sadeghi, A.
- Mark, R. J.**
- Tran, L. M.; Sercarz, J.; Fu, Y. S.; Calcaterra, T. C.; Parker, R. G.: Chondrosarcoma of the head and neck: The UCLA experience, 1955–1988, 232
- Martz, K. L.** See Laramore, G. E.
- Maruyama, Y.**
- Nagell, J. R. V.; Yoneda, J.; Gallion, H. H.; DePriest, P.; Feola, J. M.; Wierzicki, J.: Schedule in Cf-252 neutron brachytherapy: Complications after delayed implant therapy for cervical cancer in a phase II trial, 168
- Mas, E.** See Hicks, M. L.
- Masai, Y.** See Nio, Y.
- Mayer, R. J.** See Stone, R. M.
- Mcauley, M.** See Hicks, M. L.
- McLees, B.** See Homesley, H. D.
- Mehta, M. P.** See Peterit, D. G.
- Merlano, M.** See Benasso, M.
- Mertens, W. C.**
- Stitt, L.; Porter, A. T.: Strontium 89 therapy and relief of pain in patients with prostatic carcinoma metastatic to bone: A dose response relationship?, 238
- Meurk, M. L.**
- Schonberg, R. G.; Haynes, G.; Vaeth, J. M.: The development of a small, economic mobile unit for intraoperative electron beam therapy, 459
- Meyer, J. L.**
- Whole-lung irradiation for Kaposi's sarcoma, 372
- Micaily, B.** See Calvo, F. A.
- Miglietta, L.** See Pronzato, P.
- Miller, A.** See Fontanesi, J.
- Miller, M. E.** See Mandanas, R.
- Miller, M. J.**
- Kagan, A. R.; Rao, A. R.; Wollin, M.: An evaluation of the efficacy of postoperative irradiation in rectal adenocarcinoma, 402
- Mills, G. M.**
- Baethge, B. A.: Ischiogluteal bursitis in cancer patients: An infrequently recognized cause of pain, 229
- Mitchell, E. D.** See Luikart, S. D.
- Miyamoto, C.** See Seegenschmiedt, M. H.
- Mizuta, J.** See Nio, Y.
- Modeas, C. R.** See Luikart, S. D.
- Montebello, J. F.**
- Aron, B. S.; Manatunga, A. K.; Horvath, J. L.; Peyton, F. W.: The reirradiation of recurrent bronchogenic carcinoma with external beam irradiation, 482
- Monzeglio, C.** See Pronzato, P.
- Moore, M.** See Cody, R.
- Mori, K.**
- Saito, Y.; Tominaga, K.: Antiemetic efficacy of alprazolam in the combination of metoclopramide plus methylprednisolone: Double-blind randomized crossover study in patients with cisplatin-induced emesis, 338
- Möykkynen, K.** See Maiche, A. G.
- Mullin, T. J.** See Homesley, H. D.
- Murayama, S.** See Ikeda, H.
- Muss, H. B.**
- Blessing, J. A.; DuBoshter, B.: Echinomycin in recurrent and metastatic endometrial carcinoma: A phase II trial of the gynecologic oncology group, 492
- Nagell, J. R. V.** See Maruyama, Y.
- Nakajima, Y.** See Uchino, J.
- Neisler, J.** See Konski, A.
- Nio, M.** See Nio, Y.
- Nio, Y.**
- Tseng, C.; Shiraishi, T.; Tsubono, M.; Kawabata, K.; Masai, Y.; Hayashi, H.; Fukumoto, M.; Nio, M.; Sato, M.; Mizuta, J.; Tobe, T.: A phase II study of 5-fluorouracil, cisplatin, and 4'-epirubicin in the treatment of advanced solid cancers, 96
- Norkool, P.** See Finklestein, J. Z.
- Odell, P.** See Stewart, D. J.
- O'Donnell, J.** See Luikart, S. D.
- Olivier, J. P.** See Chevallier, B.
- Ong, Y.-W.** See Ang, P.-T.
- Ordóñez, A.** See Barón, M. G.
- O'Toole, R. V.** See Homesley, H. D.
- Paccagnella, A.** See Tomio, L.
- Paddock, L.** See Skillings, J. R.
- Pajak, T. F.** See Marcial, V. A.
- Paliwal, B.** See Bastin, K.
- Pancoast, J. R.** See Fletcher, W. S.
- Paradiso, A.** See Lena, M. D.
- Pardo, F.** See Hidalgo, O. F.
- Parker, R. G.** See Mark, R. J.; Sadeghi, A.
- Parkinson, D. R.** See Chang, A.
- Patterson, J. H.** See Perez, C. A.
- Pazdur, R.** See Jaiesimi, I. A.
- Pedrick, T. J.**
- Wheeler, W.; Riemenschneider, H.: Combined modality therapy for locally advanced penile squamous cell carcinoma, 501
- Pellicci, P. G.** See Davis, S.
- Perez, C. A.**
- Kirchmann, E.; Lockett, M. A.: Definitive external irradiation in stages A (T1) and B (T2) carcinoma of the prostate, 377
- Patterson, J. H.; Emami, B.: Evaluation of 45°C hyperthermia and irradiation: I. Studies in a murine rhabdomyosarcoma model, 469
- Scott, C.; Emami, B.; Hornback, N. B.; Sneed, P. K.; Asbell, S. O.; Janjan, N. A.: Evaluation of 45°C hyperthermia and irradiation: II. A phase I clinical trial in humans by the radiation therapy oncology group, 477
- Perez, J.** See Lena, M. D.
- Perrin, P.** See Petrovich, Z.
- Perry, M. C.** See Luikart, S. D.
- Peterit, D. G.**
- Mehta, M. P.; Buchler, D. A.; Kinsella, T. J.: A retrospective review of nodal treatment for vulvar cancer, 38
- Petrovich, Z.**
- Amey, F.; Baert, L.; Bichler, K. H.; Boyd, S. D.; Brady, L. W.; Bruskewitz, R. C.; Dixon, C.; Perrin, P.; Watson, G. M.: New trends in the treatment of benign prostatic hyperplasia and carcinoma of the prostate, 187
- Peyton, F. W.** See Montebello, J. F.
- Phibbs, G.** See Konski, A.
- Pisters, K. M. W.** See Kris, M. G.

- Piver, M. S. See Hicks, M. L.  
 Pola, Y. See Bastin, K.  
 Porkka, K. See Maiche, A. G.  
 Porter, A. T. See Mertens, W. C.  
 Pronzato, P.  
 —Miglietta, L.; Rubagotti, A.; Bertelli, G.; Queirolo, P.; Guenzi, M.; Sertoli, M. R.; Vitale, V.; Rosso, R.: Impact of irradiation of residual breast on adjuvant chemotherapy dose intensity, 58  
 —Rubagotti, A.; Amoroso, D.; Bertelli, G.; Queirolo, P.; Sertoli, M. R.; Rosso, M.; Gallotti, P.; Monzeglio, C.; Rosso, R.: Second-line hormonotherapy for breast cancer: Uselessness of first-line continuation, 522  
 Propert, K. J. See Luikart, S. D.  
 Przepiorka, D. See Seong, D. C.
- Queirolo, P. See Pronzato, P.
- Rabinovich, M. See Lena, M. D.  
 Rao, A. R. See Miller, M. J.  
 Raub, W. A., Jr. See Hilsenbeck, S. G.  
 Ravasz, L. A. See Levendag, P. C.  
 Rebar, R. W. See Homesley, H. D.  
 Rebattu, P. See Roché, H.  
 Rebollo, J. See Calvo, F. A.; Hidalgo, O. F.  
 Richardson, R. L. See Creagan, E. T.  
 Riemenschneider, H. See Pedrick, T. J.  
 Roche, H. See Chevallier, B.  
 Roché, H.  
 —Guiochet, N.; Kerbrat, P.; Rebattu, P.; Fargeot, P.; Cattani, A.; Armand, J. P.; Keilung, R.; Lentz, M. A.; Glabecke, M. V.; Herait, P.; Fumoleau, P.: Phase II trials of tetrahydropyranlyl-adriamycin (pirarubicin) on renal and colon carcinoma, melanoma, and soft tissue sarcoma, 137  
 Rodriguez, R. See Lena, M. D.  
 Roelstraete, A.  
 —Lancker, M. V.; Schryver, A. D.; Storme, G.: Adjuvant radiation after conservative surgery for early breast cancer: Local control and cosmetic outcome, 284  
 Romero, A. See Lena, M. D.  
 Rosso, M. See Pronzato, P.  
 Rosso, R. See Benasso, M.; Pronzato, P.  
 Rotman, M. See Marcial, V. A.  
 Rowen, J. See Goss, G. D.  
 Rubagotti, A. See Pronzato, P.  
 Russell, K. J. See Laramore, G. E.  
 Ryoo, M. C. See Chan, S. L.
- Sadeghi, A.  
 —Tran, L. M.; Mark, R.; Sidrys, J.; Parker, R. G.: Minor salivary gland tumors of the head and neck: Treatment strategies and prognosis, 3  
 Saito, Y. See Mori, K.  
 Sala, O. See Tomio, L.  
 Salter, M. See Halperin, E. C.  
 Sato, M. See Nio, Y.  
 Sato, N. See Uchino, J.  
 Sato, Y. See Uchino, J.  
 Sauer, R. See Seegenschmiedt, M. H.  
 Saxton, J. P. See Dass, K. K.  
 Schaid, D. J. See Creagan, E. T.  
 Schonberg, R. G. See Meurk, M. L.  
 Schryver, A. D. See Roelstraete, A.  
 Schutt, A. J. See Creagan, E. T.  
 Scott, C. See Perez, C. A.  
 Seegenschmiedt, M. H.  
 —Sauer, R.; Miyamoto, C.; Chahal, J. A.; Brady, L. W.: Clinical experience with interstitial thermoradiotherapy for localized implantable pelvic tumors, 210  
 Seeger, J. See Joseph, G.  
 Segati, R. See Tomio, L.  
 Seong, D. C.  
 —Przepiorka, D.; Bruner, J. M.; Tassel, P. V.; Lo, W. K.; Champlin, R. E.: Leptomeningeal toxoplasmosis after allogeneic marrow transplantation: Case report and review of the literature, 102  
 Sercarz, J. See Mark, R. J.  
 Sertoli, M. R. See Pronzato, P.  
 Shanahan, T. See Bastin, K.  
 Sheehan, R. G.  
 —Balaban, E. P.; Frenkel, E. P.: The impact of dose intensity of standard chemotherapy regimens in extensive stage small cell lung cancer, 250  
 Shemano, I. See Homesley, H. D.  
 Shields, C. L. See Hernandez, J. C.  
 Shields, J. A. See Hernandez, J. C.  
 Shimm, D. S. See Croghan, M. K.  
 Shiraishi, T. See Nio, Y.  
 Sidrys, J. See Sadeghi, A.  
 Siegel, J. See Gryn, J.  
 Skillings, J. R.  
 —Sridhar, F. G.; Wong, C.; Paddock, L.: The frequency of red cell transfusion for anemia in patients receiving chemotherapy: A retrospective cohort study, 22  
 Sledge, G. W. See Broun, E. R.  
 Slingerland, R. See de Wit, R.  
 Smith, T. J. See Chang, A.  
 Sneed, P. K. See Perez, C. A.  
 Sng, I. See Ang, P.-T.  
 Soh, L.-T. See Ang, P.-T.  
 Sondak, V. K. See Fletcher, W. S.  
 Song, C. W. See Sperduto, P. W.  
 Sperduto, P. W.  
 —Song, C. W.; Levitt, S. H.: The in vitro radiosensitization of human glioblastoma with pentoxifylline, 407  
 Spiridonidis, C. H. See Kraut, E. H.  
 Spriggs, D. R. See Stone, R. M.  
 Sridhar, F. G. See Skillings, J. R.  
 Sridhar, K. S. See Ganz, W. I.; Hilsenbeck, S. G.  
 Stewart, D. See Cody, R.  
 Stewart, D. J. See Tannock, I. F.  
 —Cripps, M. C.; Fingert, H.; Lamothe, A.; Laframboise, G.; Gerin-Lajoie, J.: Cisplatin, cytosine arabinoside, and pentoxifylline in the treatment of squamous cell carcinoma of the head and neck, 123  
 —Cripps, M. C.; Lamothe, A.; Laframboise, G.; Odell, P.; Gerin-Lajoie, J.: Doxorubicin plus metronidazole in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck, 113  
 Stitt, J. See Bastin, K.  
 Stitt, L. See Mertens, W. C.  
 Stone, R. M.  
 —Spriggs, D. R.; Arthur, K. A.; Mayer, R. J.; Griffin, J.; Kufe, D. W.: Recombinant human gamma interferon administered by continuous intravenous infusion in acute myelogenous leukemia and myelodysplastic syndromes, 159  
 Storme, G. See Roelstraete, A.  
 Stoter, G. See de Wit, R.  
 Streeter, O. E., Jr. See Chan, S. L.  
 Sulkes, A. See Fenig, E.
- Tai, D. See Fontanesi, J.  
 Tangco, E. See González-Manzano, R.; Hidalgo, O. F.  
 Tannock, I. F.  
 —Erwin, T. J.; Stewart, D. J.; Fontaine, B.; Gupta, S.: Phase II multicenter study of epirubicin for hormone-resistant prostatic cancer with measurable soft tissue disease, 156

- Tassel, P. V. See Seong, D. C.  
 Terhaard, C. H. J. See Levendag, P. C.  
 Teshima, T. See Ikeda, H.  
 Theriault, R. L.  
 —Fraschini, G.; Holmes, F. A.; Frye, D.; Gutterman, J. U.; Hortobagyi, G. N.: The myeloprotective effect of recombinant human granulocyte-macrophage colony-stimulating factor given sequentially with continuous infusion vinblastine in metastatic breast cancer patients, 132  
 Thomas, F. J. See Laramore, G. E.  
 Thomine, E. See Azagury, M.  
 Tobe, T. See Nio, Y.  
 Toma, S. See Benasso, M.  
 Tominaga, K. See Mori, K.  
 Tomio, L.  
 —Zorat, P. L.; Paccagnella, A.; Segati, R.; Loreggian, L.; Lora, O.; Friso, M. L.; Chiarion-Sileni, V.; Favaretto, A.; Fede, A.; Andreoli, C.; Francini, F.; Sala, O.; Fiorentino, M.; Calzavara, F.: A pilot study of concomitant radiation and chemotherapy in patients with locally advanced head and neck cancer, 264  
 Tonato, M. See Davis, S.  
 Townsend, R. See Fletcher, W. S.  
 Tran, L. M. See Mark, R. J.; Sadeghi, A.  
 Tricot, G. J. K. See Broun, E. R.  
 Tseng, C. See Nio, Y.  
 Tsubono, M. See Nio, Y.  
 Turner, S.  
 —(Letter), 182  
 Twigg, L. See Barrett, R. J.  
 Tyson, L. B. See Kris, M. G.
- Uchino, J.  
 —Une, Y.; Sato, Y.; Gondo, H.; Nakajima, Y.; Sato, N.: Chemohormonal therapy of unresectable hepatocellular carcinoma, 206  
 Une, Y. See Uchino, J.

- Vaeth, J. M. See Meurk, M. L.  
 Vaeth, P. A.  
 Women's knowledge about breast cancer: Dimensions of knowledge and scale development, 446  
 Valencic, S. L. See Croghan, M. K.  
 Vallejo, C. See Lena, M. D.  
 van Dijk, J. M.  
 —Hypercalcemia in prostatic carcinoma: Case report and review of the literature, 329  
 Verweij, J. See de Wit, R.  
 Vieitez, J. M. See González-Manzano, R.; Hidalgo, O. F.  
 Vincent, M. See Goss, G. D.  
 Virkkunen, P. See Maiche, A. G.  
 Vitale, V. See Pronzato, P.

- Walsh, D. L. See Hicks, M. L.  
 Watson, G. M. See Petrovich, Z.  
 Webster, K. See Dass, K. K.  
 Webster, K. D. See Barrett, R. J.  
 Weir, A. See Fontanesi, J.  
 Wentz, A. C. See Homesley, H. D.  
 Wheeler, B. See Mandanas, R.  
 Wheeler, W. See Pedrick, T. J.  
 Wierzbicki, J. See Maruyama, Y.  
 Wilson, J. F. See Erickson, B. A.  
 Wollin, M. See Miller, M. J.  
 Wong, C. See Skillings, J. R.  
 Woodcock, T. See Joseph, G.  
 Woodlief, L. See Homesley, H. D.

- Yoneda, J. See Maruyama, Y.

- Zamora, P. See Barón, M. G.  
 Zorat, P. L. See Tomio, L.  
 Zudaire, J. See Calvo, F. A.



**Statement of Ownership,  
Management and  
Circulation**  
(Required by 39 U.S.C. 3685)

|  |  |  |  |
|--|--|--|--|
| 1. Title of Publication<br>American Journal of Clinical Oncology,<br>Cancer Clinical Trials  |  | 2. Date of Filing<br>Oct 1, 1993   |  |
| 3. Frequency of Issue<br>Bi-monthly  |  | 4. Issue for this month<br>6   |  |
| 5. Complete Mailing Address of Known Office of Publication (Street, City, County, State and ZIP+4 Code) (Do not print)   |  | 6. Complete Mailing Address of Headquarters or General Business Office of Publisher (Do not print) |  |
| 1185 Avenue of the Americas, New York, NY 10036  |  | 1185 Avenue of the Americas, New York, NY 10036  |  |
| 7. Full Names and Complete Mailing Addresses of Publisher, Editor, and Managing Editor (Do not print)  |  |  |  |
| Raven Press, 1185 Avenue of the Americas, New York, NY 10036   |  |  |  |
| 8. Editor (Do not print)   |  |  |  |
| Dr. Luther W. Brady, Dept of Radiation Oncology and Nuclear Medicine Hahnemann University<br>Broad and Vine Streets, MS 200 Philadelphia, PA 19102                       |  |  |  |
| 9. Owner (Do not print)  |  |  |  |
| Ed Barnes, Raven Press, 1185 Avenue of the Americas, New York, NY 10036  |  |  |  |
| 10. Known Bondholders, Mortgagees, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages or Other Securities (Do not print) |  |  |  |
| NONE   |  |  |  |
| 11. For Completion by Nonprofit Organizations Authorized to Mail at Special Rates (Form 3541-10-1)   |  |  |  |
| The purpose, function, and nonprofit status of this organization and the exempt status for Federal income tax purposes (Do not print)                                    |  |  |  |
| 12. Tax Status (Do not print)  |  |  |  |
| 13. Tax Status (Do not print)  |  |  |  |
| 14. Tax Status (Do not print)  |  |  |  |
| 15. Tax Status (Do not print)  |  |  |  |
| 16. Tax Status (Do not print)  |  |  |  |
| 17. Tax Status (Do not print)  |  |  |  |
| 18. Tax Status (Do not print)  |  |  |  |
| 19. Tax Status (Do not print)  |  |  |  |
| 20. Tax Status (Do not print)  |  |  |  |
| 21. Tax Status (Do not print)  |  |  |  |
| 22. Tax Status (Do not print)  |  |  |  |
| 23. Tax Status (Do not print)  |  |  |  |
| 24. Tax Status (Do not print)  |  |  |  |
| 25. Tax Status (Do not print)  |  |  |  |
| 26. Tax Status (Do not print)  |  |  |  |
| 27. Tax Status (Do not print)  |  |  |  |
| 28. Tax Status (Do not print)  |  |  |  |
| 29. Tax Status (Do not print)  |  |  |  |
| 30. Tax Status (Do not print)  |  |  |  |
| 31. Tax Status (Do not print)  |  |  |  |
| 32. Tax Status (Do not print)  |  |  |  |
| 33. Tax Status (Do not print)  |  |  |  |
| 34. Tax Status (Do not print)  |  |  |  |
| 35. Tax Status (Do not print)  |  |  |  |
| 36. Tax Status (Do not print)  |  |  |  |
| 37. Tax Status (Do not print)  |  |  |  |
| 38. Tax Status (Do not print)  |  |  |  |
| 39. Tax Status (Do not print)  |  |  |  |
| 40. Tax Status (Do not print)  |  |  |  |
| 41. Tax Status (Do not print)  |  |  |  |
| 42. Tax Status (Do not print)  |  |  |  |
| 43. Tax Status (Do not print)  |  |  |  |
| 44. Tax Status (Do not print)  |  |  |  |
| 45. Tax Status (Do not print)  |  |  |  |
| 46. Tax Status (Do not print)  |  |  |  |
| 47. Tax Status (Do not print)  |  |  |  |
| 48. Tax Status (Do not print)  |  |  |  |
| 49. Tax Status (Do not print)  |  |  |  |
| 50. Tax Status (Do not print)  |  |  |  |
| 51. Tax Status (Do not print)  |  |  |  |
| 52. Tax Status (Do not print)  |  |  |  |
| 53. Tax Status (Do not print)  |  |  |  |
| 54. Tax Status (Do not print)  |  |  |  |
| 55. Tax Status (Do not print)  |  |  |  |
| 56. Tax Status (Do not print)  |  |  |  |
| 57. Tax Status (Do not print)  |  |  |  |
| 58. Tax Status (Do not print)  |  |  |  |
| 59. Tax Status (Do not print)  |  |  |  |
| 60. Tax Status (Do not print)  |  |  |  |
| 61. Tax Status (Do not print)  |  |  |  |
| 62. Tax Status (Do not print)  |  |  |  |
| 63. Tax Status (Do not print)  |  |  |  |
| 64. Tax Status (Do not print)  |  |  |  |
| 65. Tax Status (Do not print)  |  |  |  |
| 66. Tax Status (Do not print)  |  |  |  |
| 67. Tax Status (Do not print)  |  |  |  |
| 68. Tax Status (Do not print)  |  |  |  |
| 69. Tax Status (Do not print)  |  |  |  |
| 70. Tax Status (Do not print)  |  |  |  |
| 71. Tax Status (Do not print)  |  |  |  |
| 72. Tax Status (Do not print)  |  |  |  |
| 73. Tax Status (Do not print)  |  |  |  |
| 74. Tax Status (Do not print)  |  |  |  |
| 75. Tax Status (Do not print)  |  |  |  |
| 76. Tax Status (Do not print)  |  |  |  |
| 77. Tax Status (Do not print)  |  |  |  |
| 78. Tax Status (Do not print)  |  |  |  |
| 79. Tax Status (Do not print)  |  |  |  |
| 80. Tax Status (Do not print)  |  |  |  |
| 81. Tax Status (Do not print)  |  |  |  |
| 82. Tax Status (Do not print)  |  |  |  |
| 83. Tax Status (Do not print)  |  |  |  |
| 84. Tax Status (Do not print)  |  |  |  |
| 85. Tax Status (Do not print)  |  |  |  |
| 86. Tax Status (Do not print)  |  |  |  |
| 87. Tax Status (Do not print)  |  |  |  |
| 88. Tax Status (Do not print)  |  |  |  |
| 89. Tax Status (Do not print)  |  |  |  |
| 90. Tax Status (Do not print)  |  |  |  |
| 91. Tax Status (Do not print)  |  |  |  |
| 92. Tax Status (Do not print)  |  |  |  |
| 93. Tax Status (Do not print)  |  |  |  |
| 94. Tax Status (Do not print)  |  |  |  |
| 95. Tax Status (Do not print)  |  |  |  |
| 96. Tax Status (Do not print)  |  |  |  |
| 97. Tax Status (Do not print)  |  |  |  |
| 98. Tax Status (Do not print)  |  |  |  |
| 99. Tax Status (Do not print)  |  |  |  |
| 100. Tax Status (Do not print)   |  |  |  |

## SUBJECT INDEX FOR VOLUME 16

- Acquired immune deficiency syndrome, whole-lung irradiation for Kaposi's sarcoma in, 372
- Age factor, external beam irradiation in prostate cancer and, 140
- Alpha interferon
  - with carboplatin, in metastatic non-small cell lung cancer, 519
  - chemotherapy and, in advanced squamous cell carcinoma of head and neck, 465
- Alprazolam, in cisplatin-induced emesis, 338
- Aminogluthetamide, in breast cancer, 522
- Amonafide, in epithelial ovarian cancer, 529
- Amphotericin B
  - with doxorubicin, dacarbazine and ifosfamide, in metastatic soft tissue sarcomas, 332
  - inhaled, toxicity of, 43
- Anal canal, recurrent metastatic squamous cell carcinoma of, 5-fluorouracil with cisplatin in, 536
- Anemia, red cell transfusion in, 22
- Anthracyclines, cardiotoxicity of, 109
- Antiemetic, with high-dose metoclopramide, 175
- Antiestrogens, in postmenopausal women, 117
- Arabinosyl-5-azacytosine, in embryonal cell carcinoma, 34
- Astrocytoma, diaziquone vs. carmustine in, 277
- Balloon dilatation, of prostate, 187
- Biological response modifier, in acute myeloid leukemia and myelodysplastic syndromes, 159
- Bladder, cancer of, intraoperative and preoperative radiation therapy in, 61
- Bleomycin
  - high-dose, continuous infusion, in poor prognostic testicular cancer, 323
  - with mitoxantrone, in malignant pleural effusion, 50
  - with VP-16, cisplatin and doxorubicin, in metastatic Merkel cell carcinoma, 102
  - with VP-16 and cisplatin, in advanced nonsquamous cell head and neck neoplasm, 291
- Bone, prostatic carcinoma metastatic to, strontium 89 therapy for pain relief in, 238
- Bone marrow transplantation
  - in advanced breast cancer, with high-dose carboplatin and mitoxantrone, 9
  - leptomeningeal toxoplasmosis after, 105
- Brachytherapy
  - high-dose vs. low-dose, in gynecologic cancer, 256
  - nasopharyngeal, 424
  - neutron, CF-252, delayed, in cervical cancer, 168
  - plaque, in retinoblastoma, 397
- Brain, malignant tumor of, diaziquone vs. carmustine in, 277
- Breast, cancer of
  - advanced
    - brequinar sodium in, 526
    - high-dose carboplatin and mitoxantrone in, with autologous bone marrow support, 9
    - mitomycin-C in, vs. mitomycin-C plus high-dose medroxyprogesterone acetate, 14
  - early, adjuvant radiation after conservative surgery in, 284
  - inflammatory, intensive chemotherapy in, 223
  - radiotherapy and chemotherapy dose intensity in, 58
  - recombinant human granulocyte-macrophage colony-stimulating factor in, 132
  - second-line hormonotherapy in, 522
  - stage IV, metastatic pattern and DNA ploidy in, 245
  - subungual metastasis of, mimicking acute paronychia of great toe, 87
  - two decades of treatment in, 532
  - women's knowledge about, 446
- Brequinar sodium, in advanced breast cancer, 526
- Bronchus, recurrent carcinoma of, external beam irradiation in, 482
- Bursitis, ischiogluteal, 229
- Cancer and Leukemia Group B, phase I-II trial of etoposide and carboplatin in extensive small cell lung cancer, 127
- Carboplatin
  - with alpha interferon, in metastatic non-small cell lung cancer, 519
  - with etoposide, in extensive small cell lung cancer, 127
  - with 5-fluorouracil, intra-arterial hepatic treatment and, 30
  - high-dose, mitoxantrone and, in advanced breast cancer, 9
  - in melanoma, 152
  - with teniposide, in small cell lung cancer, 295
- Cardiotoxicity, of anthracyclines, 109
- Carmustine, in primary malignant brain tumor, 277
- Cervix
  - advanced squamous cell carcinoma of, tricyclic nucleoside phosphate in, 506
  - cancer of, delayed implant therapy in, 168
- CF-252 neutron brachytherapy, delayed, in cervical cancer, 168
- Chemohormonal therapy, in hepatocellular carcinoma, 206
- Chemotherapy. *See also* names of specific agents and conditions
  - alpha-interferon and, in advanced squamous cell carcinoma of head and neck, 465
  - in bladder cancer, tumor downstaging and, 61
  - in breast cancer, impact of radiation therapy on chemotherapy dose intensity in, 58
  - intensive induction, in inflammatory breast cancer, 223
  - in malignant mixed mullerian tumors of ovary, 346
  - postoperative, in stage I-II small cell lung cancer, 93
  - radiation therapy and
    - in locally advanced head and neck cancer, 264
    - in locally advanced penile squamous cell carcinoma, 501
  - red cell transfusion for anemia and, 22
- Chlorambucin, high-dose, with dexamethasone, in relapsed non-Hodgkin's lymphoma, 319
- Chondrosarcoma, of head and neck, 232
- Cisplatin
  - with cytosine arabinoside and pentoxifylline, in squamous cell carcinoma of head and neck, 123
  - with doxorubicin, bleomycin and VP-16, in metastatic Merkel cell carcinoma, 102
  - with doxorubicin, in advanced endometrial carcinoma, 494
  - with DTIC, in inoperable melanoma, 359
  - emesis control and, 175
  - with 5-fluorouracil, in recurrent metastatic squamous cell carcinoma of anal canal, 536



- with 5-fluorouracil and 4'-epirubicin, in advanced solid cancers, 96
- in locally advanced head and neck cancer, 264
- in malignant supratentorial glioma, 412
- with mitomycin and ifosfamide vs. vindesine, ifosfamide and cisplatin, in non-small cell lung cancer, 310
- ondansetron and, 77
- with vindesine, and ifosfamide vs. mitomycin, ifosfamide and cisplatin, in non-small cell lung cancer, 310
- with VP-16 and bleomycin, in advanced nonsquamous cell head and neck neoplasia, 291
- CNS Cancer Consortium, diaziquone vs. carmustine in, 277
- <sup>60</sup>Cobalt, in retinoblastoma, 397
- Colon, carcinoma of, tetrahydropyran adriamycin in, 137
- Colony stimulating factors, in breast cancer, 132
- Colorectal carcinoma, 5-fluorouracil and carboplatin in metastases from, 30
- Computer-aided documentation, 455
- Congestive heart failure, doxorubicin-induced, 109
- Corticosteroids, in ischiogluteal bursitis, 229
- Cutaneous paraneoplastic syndromes, associated with laryngeal and lung malignancies, 268
- Cyclophosphamide
  - with doxorubicin and vincristine, in stage I-II small cell lung cancer, 93
  - with methotrexate and 5-fluorouracil, in Merkel cell carcinoma, 54
- Cytosine arabinoside, with pentoxifylline and cisplatin, in squamous cell carcinoma of head and neck, 123
- Dacarbazine, with doxorubicin and ifosfamide plus amphotericin B, in metastatic soft tissue sarcoma, 332
- Database, 455
- Debulking, para-aortic metastases from gynecologic tumor and, 67
- Dexamethasone, with high-dose chlorambucil, in relapsed non-Hodgkin's lymphoma, 319
- Diaziquone, in primary malignant brain tumor, 277
- Didemnin B
  - in previously treated epithelial ovarian cancer, 47
  - toxicity of, 47
- 5,6-Dihydro-5-azacytidine hydrochloride, in disseminated malignant melanoma, 243
- DNA ploidy, in stage IV breast cancer, 245
- Documentation, computer-aided, 455
- Doxorubicin
  - with cisplatin, bleomycin and VP-16, in metastatic Merkel cell carcinoma, 102
  - with cisplatin, in advanced endometrial carcinoma, 494
  - with ifosfamide and dacarbazine plus amphotericin B, in metastatic soft tissue sarcomas, 332
  - with metronidazole, in recurrent or metastatic squamous cell carcinoma of head and neck, 113
  - with vincristine and cyclophosphamide, in stage I-II small cell lung cancer, 93
- DTIC, with cisplatin, in inoperable melanoma, 359
- Dyspnea, whole-lung irradiation for Kaposi's sarcoma and, 372
- Early Breast Cancer Trialists' Collaborative Group, systemic adjuvant breast cancer therapy and, 532
- Eastern Cooperative Oncology Group
  - EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma, 342
  - phase II trial of carboplatin in metastatic malignant melanoma, 152
- Echinomycin, in recurrent and metastatic endometrial carcinoma, 492
- Effusion, pleural, malignant, bleomycin and mitoxantrone in, 50
- Ehrlich, Clarence E., 185
- Ejection fraction, left ventricular, anthracycline cardiotoxicity and, 109
- Electron beam radiation therapy
  - intraoperative, mobile unit for, 459
  - in para-aortic metastases from gynecologic tumor, 67
- Embryonal cell carcinoma, fazarabine in, 34
- Endometrium, cancer of
  - advanced or recurrent, vincristine in, 18
  - doxorubicin-cisplatin chemotherapy in, 494
  - echinomycin in, 492
- Ependymoma, spinal cord, surgery and radiation therapy in, 350
- 4'-Epirubicin, with 5-fluorouracil and cisplatin, in advanced solid cancers, 96
- Epithelial ovarian cancer
  - amonafile in, 529
  - didemnin B in, 47
  - medroxyprogesterone acetate in, 149
- Estradiol, antiestrogens and, in postmenopausal women, 117
- Etoposide, with carboplatin, in extensive small cell lung cancer, 127
- External beam irradiation
  - age-race interaction in prostate cancer and, 140
  - in recurrent bronchogenic carcinoma, 482
- Fazarabine, in embryonal cell carcinoma, 34
- 5-Fluorouracil
  - carboplatin and, intra-arterial hepatic treatment with, in metastases from colorectal carcinoma, 30
  - with cisplatin, in recurrent metastatic squamous cell carcinoma of anal canal, 536
  - with cisplatin and 4'-epirubicin, in advanced solid cancers, 96
  - with cyclophosphamide and methotrexate, in Merkel cell carcinoma, 54
  - in locally advanced head and neck cancer, 264
- Fungal pneumonia, inhaled amphotericin B and, 43
- Gated cardiac scan, anthracycline cardiotoxicity and, 109
- Glioblastoma
  - diaziquone vs. carmustine in, 277
  - pentoxifylline in, 407
- Glioma
  - diaziquone vs. carmustine in, 277
  - supratentorial, malignant, concomitant cisplatin and hyperfractionated external beam irradiation in, 412
- Granulocyte-macrophage colony-stimulating factor, in breast cancer, 132
- Gynecologic cancer
  - high-dose vs. low-dose brachytherapy in, 256
  - recurrent, intraoperative orthovoltage radiation therapy in, 497
- Gynecologic Oncology Group
  - didemnin B in previously treated epithelial ovarian cancer, 47
  - participating institutions and National Cancer Institute Grants, 18
  - phase II study of amonafile in epithelial ovarian cancer, 529
  - phase II trial of medroxyprogesterone acetate in epithelial ovarian cancer, 149
  - phase II trial of vincristine in advanced or recurrent endometrial carcinoma, 18
- Head and neck
  - cancer of
    - chondrosarcoma as, 232
    - concomitant alpha-interferon and chemotherapy in, 465
    - concomitant radiation and chemotherapy in, 264
    - squamous cell
      - cisplatin, cytosine arabinoside and pentoxifylline in, 123

- "compensated" split-course vs. continuous radiation therapy in, 389
  - metronidazole with doxorubicin in, 113
  - VP-16, bleomycin and cisplatin in, 291
  - indolent non-Hodgkin's lymphoma of, 72
  - minor salivary gland tumors of, 3
- Hepatocellular carcinoma, chemohormonal therapy in, 206
- Hormone-refractory metastatic adenocarcinoma of prostate, mitoxantrone in, 489
- Hormonotherapy, second-line, in breast cancer, 522
- 5-HT<sub>3</sub>, with high-dose metoclopramide, 175
- Hydrocortisone acetate, in breast cancer, 522
- Hypercalcemia, in prostatic carcinoma, 329
- Hyperperthermia, local, biological effects of, 187
- Hyperplasia, prostatic, benign, new treatments in, 187
- Hypertension, diastolic, in Wilms' tumor, 201
- Hyperthermia
  - interstitial, localized pelvic tumors and, 210
  - microwave, transurethral, 187
  - radiation therapy and in humans, 477
  - in murine rhabdomyosarcoma model, 469
  - regional, with systemic warming, 354
  - transrectal, 187
- Ifosfamide
  - with doxorubicin and dacarbazine plus amphotericin B, in metastatic soft tissue sarcomas, 332
  - with mitomycin and cisplatin vs. vindesine, ifosfamide and cisplatin, in non-small cell lung cancer, 310
- Inguinofemoral irradiation, in vulvar cancer, 38
- Inhalation therapy, toxicity of, 43
- Interferon-gamma, in acute myelogenous leukemia and myelodysplastic syndromes, 159
- Intra-arterial infusion chemotherapy
  - hepatic, with carboplatin and 5-fluorouracil, in metastases from colorectal carcinoma, 30
  - in unresectable hepatocellular carcinoma, 206
- Iodine
  - in malignant supratentorial glioma, 412
  - in retinoblastoma, 397
- Iridium
  - in localized pelvic tumors, 210
  - in retinoblastoma, 397
- Kaposi's sarcoma, whole-lung irradiation in, 372
- Karnofsky index, 26
- Kidney, carcinoma of, tetrahydropyran adriamycin in, 137
- Larynx, cancer of
  - hypertrophic pulmonary osteoarthropathy and tripe palms in, 268
  - squamous cell, split-course radiation protocol in, 509
- Laser prostatectomy, 187
- Leptomeningeal toxoplasmosis, after allogeneic marrow transplantation, 105
- Leukemia, acute, myelogenous, interferon-gamma in, 159
- Liver, metastases to, intra-arterial hepatic treatment with carboplatin and 5-fluorouracil in, 30
- Lung, cancer of
  - external beam irradiation in, 482
  - hypertrophic pulmonary osteoarthropathy and tripe palms in, 268
  - multivariate analysis of prognostic factors in, 301
  - non-small cell, carboplatin with alpha interferon in, 519
  - small cell
    - extensive stage, dose intensity of standard chemotherapy and, 250
    - scarboplatin with etoposide in, 127
- Stage I-II, 93
  - teniposide with carboplatin in, 295
- Lymph node, metastases to, minor salivary gland tumors and, 3
- Lymphadenectomy, in vulvar cancer, 38
- Lymphoma. *See* Non-Hodgkin's lymphoma
- MACOP-B, in advanced non-Hodgkin's lymphoma, 315
- Magnetic resonance imaging, in leptomeningeal toxoplasmosis after bone marrow transplantation, 105
- McElwain, Timothy, 1
- MDL 72,222, with high-dose metoclopramide, 175
- Medroxyprogesterone acetate
  - in epithelial ovarian cancer, 149
  - high-dose, plus mitomycin, in advanced breast cancer, 14
- Melanoma
  - disseminated, 5,6-dihydro-5-azacytidine hydrochloride in, 243
  - inoperable, cisplatin with DTIC in, 359
  - metastatic, carboplatin in, 152
  - tetrahydropyran adriamycin in, 137
- Memorial
  - Clarence E. Ehrlich, M.D., 185
  - Professor Timothy McElwain, 1
- Meningitis, leptomeningeal toxoplasmosis after bone marrow transplantation and, 105
- Merbarone, in pancreatic carcinoma, 327
- Merkel cell carcinoma
  - bleomycin with VP-16, cisplatin and doxorubicin in, 102
  - 5-fluorouracil with methotrexate and cyclophosphamide in, 54
- Methotrexate, with 5-fluorouracil and cyclophosphamide, in Merkel cell carcinoma, 54
- Methotrexate analog, toxicity with, 146
- Methylprednisolone, with metoclopramide plus alprazolam, 338
- Metoclopramide
  - high-dose, with serotonin type 3 receptor antagonist, 175
  - with methylprednisolone plus alprazolam, 338
- Metronidazole, with doxorubicin, in recurrent or metastatic squamous cell carcinoma of head and neck, 113
- Microwave hyperthermia, transurethral, 187
- Mitomycin, with ifosfamide and cisplatin vs. vindesine, ifosfamide and cisplatin, in non-small lung cancer, 310
- Mitomycin-C
  - plus high-dose medroxyprogesterone acetate, vs. mitomycin-C, in advanced breast cancer, 14
- Mitoxantrone
  - bleomycin and, in malignant pleural effusion, 50
  - continuous-infusion, in hormone-refractory metastatic adenocarcinoma of prostate, 489
  - high-dose carboplatin and, in advanced breast cancer, 9
- Mucoepidermoid carcinoma, 3
- Muga scan, anthracycline cardiotoxicity and, 109
- Mullerian tumor, mixed, malignant, of ovary, 346
- Myelodysplastic syndrome, interferon-gamma in, 159
- Nasopharynx, cancer of, brachytherapy in, 424
- National Wilms' Tumor Study Group, diastolic hypertension in Wilms' tumor and, 201
- Nausea
  - ondansetron in, 77
  - serotonin type 3 receptor antagonist and, 175
- Neck. *See* Head and neck
- Neutron radiotherapy, in prostate cancer, 164
- Neutropenia, inhaled amphotericin B and, 43
- Non-Hodgkin's lymphoma
  - advanced, MACOP-B in, 315
  - indolent, of head and neck, 72
  - relapsed, high-dose chlorambucin and dexamethasone in, 319
- Non-small cell lung cancer
  - carboplatin plus alpha interferon in, 519

- mitomycin, ifosfamide and cisplatin vs. vindesine, ifosfamide and cisplatin in, 310
- Nonsquamous cell head and neck cancer, VP-16, bleomycin and cisplatin in, 291
- Ondansetron, cisplatin and, 77
- Oral cavity, lesions of, 3
- Oriectomy, in embryonal cell carcinoma, 34
- Osteoarthropathy, pulmonary, hypertrophic, tripe palms and, 268
- Ovary, epithelial cancer of  
amonaide in, 529  
didemnin B in, 47  
medroxyprogesterone acetate in, 149
- Pain  
ischioogluteal bursitis as cause of, 229  
radiation therapy for, advanced cancer and, 444  
strontium 89 therapy in, prostatic carcinoma metastatic to bone and, 238
- <sup>109</sup>Palladium, in retinoblastoma, 397
- Pancreas  
cancer of, merbarone in, 327  
extramedullary plasmacytoma of, 363
- Para-aortic metastases, from gynecologic tumor  
debulking and, 67  
intraoperative electron beam radiation therapy in, 67
- Paranasal sinuses, tumor of, 3
- Paraneoplastic syndromes, cutaneous, associated with laryngeal and lung malignancies, 268
- Peak filling rate, anthracycline cardiotoxicity and, 109
- Pediatrics, Wilms' tumor in, diastolic hypertension and, 201
- Pelvis, localized tumors of, interstitial thermoradiotherapy in, 210
- Penis, squamous cell carcinoma of, combined modality therapy in, 501
- Pentoxifylline  
with cisplatin and cytosine arabinoside, in squamous cell carcinoma of head and neck, 123  
in glioblastoma, 407
- Pharynx, tumor of, 3
- Pirarubicin, in renal and colon carcinoma, melanoma, and soft tissue sarcoma, 137
- Piritrexim, pulmonary toxicity with, 146
- Plaque brachytherapy, in retinoblastoma, 397
- Plasmacytoma, extramedullary, of pancreas, 363
- Pleural effusion, malignant, bleomycin and mitoxantrone in, 50
- Pneumonia, fungal, inhaled amphotericin B and, 43
- Postmenopausal women, tamoxifen with toremifene in, 117
- Progesterone, in epithelial ovarian cancer, 149
- Prostate  
benign hyperplasia of, new treatments in, 187  
cancer of  
age-race interaction in, external beam irradiation and, 140  
epirubicin in, 156  
fast neutron radiotherapy in, 164  
hypercalcemia in, 329  
metastatic, hormone-refractory, mitoxantrone in, 489  
new treatments in, 187  
stages A (T1) and B (T2), definitive external irradiation in, 377  
strontium 89 therapy for pain relief in bone metastasis and, 238
- Prostatectomy, laser, 187
- Provera, epithelial ovarian cancer and, 149
- Pulmonary toxicity, with piritrexim, 146
- Race, external beam irradiation in prostate cancer and, 140
- Radiation injury, 81
- Radiation therapy  
in central nervous system cancer, diaziquone vs. carmustine in, 277  
chemotherapy and  
in locally advanced head and neck cancer, 264  
in locally advanced penile squamous cell carcinoma, 501  
"compensated" split-course vs. continuous, in carcinoma of tonsillar fossa, 389  
complications from, 81  
in early breast cancer, 284  
electron beam, intraoperative  
mobile unit for, 459  
in para-aortic metastases from gynecologic tumor, 67  
external beam  
age-race interaction in prostate cancer and, 140  
hyperfractionated, in malignant supratentorial glioma, 412  
in recurrent bronchogenic carcinoma, 482  
fast neutron, in prostate cancer, 164  
hyperthermia and  
in humans, 477  
in murine rhabdomyosarcoma model, 469  
in indolent non-Hodgkin's lymphoma of head and neck, 72  
intraoperative, 418  
in invasive bladder cancer, 61  
orthovoltage, in recurrent gynecologic malignancies, 497  
in para-aortic metastases from gynecologic tumor, 67  
in malignant mixed mullerian tumors of ovary, 346  
in minor salivary gland tumor of head and neck, 3  
for pain in advanced cancer, 444  
postoperative, in rectal adenocarcinoma, 402  
preoperative, in invasive bladder cancer, 61  
in prostate carcinoma, 377  
of residual breast, adjuvant chemotherapy dose intensity and, 58  
split-course, in squamous cell carcinoma of larynx, 509  
surgery and, in spinal cord ependymoma, 350  
in vulvar cancer, 38  
whole lung, in Kaposi's sarcoma, 372
- Radiation Therapy Oncology Group  
clinical trial of "compensated" split-course vs. continuous radiation therapy of carcinoma of tonsillar fossa, 389  
evaluation of hyperthermia and irradiation in humans, 477
- Radioactive plaque treatment, in retinoblastoma, 397
- Radiosensitization, of glioblastoma, pentoxifylline and, 407
- Recombinant human erythropoietin, in chemotherapy-induced anemia, 22
- Recombinant human gamma interferon, in acute myelogenous leukemia and myelodysplastic syndromes, 159
- Recombinant human granulocyte-macrophage colony-stimulating factor, in breast cancer, 132
- Rectum  
adenocarcinoma of, postoperative irradiation in, 402  
localized tumors of, interstitial thermoradiotherapy in, 210
- Red cell transfusion, in chemotherapy-induced anemia, 22
- Retinoblastoma, plaque brachytherapy in, 397
- Rhabdomyosarcoma, hyperthermia and radiation therapy in, 469
- <sup>106</sup>Ruthenium, in retinoblastoma, 397
- Salivary gland, minor, malignant tumors of, 3
- Sarcoma  
Kaposi's, whole-lung irradiation for Kaposi's sarcoma and, 372  
soft tissue  
doxorubicin, ifosfamide and dacarbazine plus amphotericin B in, 332  
tetrahydropyran adriamycin in, 137
- Serotonin type 3 receptor antagonist, with high-dose metoclopramide, 175
- Sex hormone therapy, in hepatocellular carcinoma, 206

- Small cell lung cancer  
 carboplatin with etoposide in, 127  
 carboplatin with teniposide in, 295  
 extensive stage, dose intensity of standard chemotherapy and, 250  
 stage I-II, postoperative chemotherapy in, 93
- Soft tissue sarcoma  
 doxorubicin with fosfamide and dacarbazine plus amphotericin B in, 332  
 tetrahydropyran adriamycin in, 137
- Software, 455
- Southwest Oncology Group  
 evaluation of cisplatin with DTIC in inoperable melanoma, 359  
 phase II trial of merbarone in pancreatic carcinoma, 327
- Squamous cell carcinoma  
 of anal canal, 5-fluorouracil with cisplatin in, 536  
 of cervix, tricyclic nucleoside phosphate in, 506  
 of head and neck  
 cisplatin, cytosine arabinoside and pentoxifylline in, 123  
 "compensated" split-course vs. continuous radiation therapy in, 389  
 concomitant alpha-interferon and chemotherapy in, 465  
 metronidazole, with doxorubicin, 113  
 of larynx, split-course radiation protocol in, 509  
 penile, combined modality therapy in, 501  
 of vulva, nodal treatment in, 38
- Strontium 89 therapy, in prostatic carcinoma metastatic to bone, 238
- Surgery  
 conservative, in early breast cancer, postoperative radiation and, 284  
 radiation therapy and, in spinal cord ependymoma, 350
- Tamoxifen  
 in breast cancer, 522  
 with toremifene, in postmenopausal women, 117
- Teniposide, with carboplatin, in small cell lung cancer, 295
- Testis, cancer of, continuous infusion of high-dose bleomycin in, 323
- Tetrahydropyran adriamycin, in renal and colon carcinoma, melanoma, and soft tissue sarcoma, 137
- Thermoradiotherapy  
 hyperthermia and, in humans, 477  
 interstitial, in localized implantable pelvic tumors, 210  
 in murine rhabdomyosarcoma model, 469
- Thermotherapy, transurethral, 187
- Thymoma, cisplatin in, 342
- Tonsillar fossa, cancer of, "compensated" split-course vs. continuous radiation therapy in, 389
- Toremifene, with tamoxifen, in postmenopausal women, 117
- Toxicity  
 with didemnin B, 47  
 with inhalation therapy, 43  
 with piritrexim, 146  
 regional hyperthermia with systemic warming and, 354
- Toxoplasmosis, leptomenigeal, after bone marrow transplantation, 105
- Transfusion, red cell, in chemotherapy-induced anemia, 22
- Transrectal hyperthermia, 187
- Transurethral thermotherapy, 187
- Tricyclic nucleoside phosphate, in advanced squamous cell carcinoma of cervix, 506
- Unknown primary, cancer of, 26
- Uterus, localized tumors of, interstitial thermoradiotherapy in, 210
- Vaeth, J.M., 369, 371
- Vinblastine, continuous infusion, with recombinant human granulocyte-macrophage colony-stimulating factor, in metastatic breast cancer, 132
- Vincristine  
 in advanced or recurrent endometrial carcinoma, 18  
 with cyclophosphamide and doxorubicin, in stage I-II small cell lung cancer, 93
- Vindesine, with ifosfamide and cisplatin vs. mitomycin, ifosfamide and cisplatin, in non-small lung cancer, 310
- Vomiting  
 ondansetron in, 77  
 serotonin type 3 receptor antagonist and, 175
- VP-16  
 with cisplatin, doxorubicin and bleomycin, in metastatic Merkel cell carcinoma, 102  
 with cisplatin and bleomycin, in advanced nonsquamous cell head and neck neoplasia, 291
- Vulva, cancer of, nodal treatment in, 38
- Wilms' tumor, diastolic hypertension in, 201



